Использование ингибитора АПФ зофеноприла при лечении пароксизмальной формы фибрилляции предсердий
https://doi.org/10.18705/1607-419X-2007-13-3-197-201
Аннотация
Об авторе
Б. А. ТатарскийРоссия
Список литературы
1. Kannel W., Wolf P., Benjamin E. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
2.
3. Benajmim E., Levy D., Vaziri S. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 1994;171:840-44
4.
5. Кушаковский М.С.. Фибрилляция предсердий (причины, механизмы, клинические формы, лечение и профилактика) Санкт-Петербург 1999; 175
6.
7. Freestone B, Lip G.. Epidemiology and costs of cardiac arrhythmias. In: Lip G. Godtfredsen J (eds).Cardiac Arrhythmias: A Clinical Approach Mosby: Edinburgh 2003; pp 3?24.
8.
9. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: Eur. Heart J., August 1, 2006; 27(16): 1979-2030.
10.
11. Lip G, Tello-Montoliu A. Management of atrial fibrillation. Heart, August 1, 2006; 92(8):1177-1182.
12.
13. Freestone B, Beevers D, Lip G. The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target? J Hum Hypertens 2004; 18: -61?465.
14.
15. Li D, Shinagawa K, Pang L. Effects of angiotensin- converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;10-:2608-261
16.
17. Kober L, Torp-Pedersen C, Carlsen J et al. A clinical trial of the angiotensin converting enzyme inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 1995;333:1670-1676.
18.
19. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study. Eur. Heart J. 2003;2-:2090-2098
20.
21. Vermes E, Tardif J, Bourassa M. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-2931.
22.
23. Madrid A, Bueno M, Rebollo J. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336.
24.
25. Jeff S. Crystal E, Garfinkle M et al. Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Meta-Analysis. J Am Coll Cardiol, 2005; -5:1832-1839.
26.
27. Б.А.Татарский Использование ингибиторов АПФ при лечении пароксизмальной формы фибрилляции предсердий. Российский кардиологический журнал, 2005;.3:58-63.
28.
29. Ehrlich J, Hohnloser S, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur. Heart J., March 1, 2006; 27(5): 512-518.
30.
31. Miller J., Zipes D. Management of the patient with cardiac arrhithmias. A textbook of cardiovascular medicine. Philadelphia: W. B. Saunders company. 2001. P. 731-736.
32.
33. Shi Y, Ducharme A, Nattel S, et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation Cardiovasc Res 2001;52:217-225.
34.
35. Van Wagoner D, Nerbonne J. Molecular basis of electrical remodeling in atrial fibrillation. J. Mol Cell Cardiol. 2000;32:1101-1117.
36.
37. Yu W, Chen S, Lee S, et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs. Circulation. 1998;97:2331-2337.
38.
39. Swedberg K, Pfeffer M, Coen-Solal A et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan results from the CHARM study. J Am Coll Cardiol 2004;43(Suppl A).
40.
41. Choudhury A, Varughese G, Lip G. Targeting the Renin Angiotensin Aldosterone System in Atrial Fibrillation: a shift from electrical to structural therapy? Exp Opin Pharmacother 2005.
42.
43. Nakashima H, Kumagai K, Urata H. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-2617.
44.
45. Borghi C., Bacchelli S., Esposti D.D., Ambrosioni E.A review of the angiotensin converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. - Expert Opinion on Pharmacotherapy, 2004; 5 (9):1965-1977.
46.
Рецензия
Для цитирования:
Татарский Б.А. Использование ингибитора АПФ зофеноприла при лечении пароксизмальной формы фибрилляции предсердий. Артериальная гипертензия. 2007;13(3):197-201. https://doi.org/10.18705/1607-419X-2007-13-3-197-201
For citation:
Tatarskyi B.A. Application of an angiotensin)converting enzyme inhibitor zofenopril in patients with paroxismal form of atrial fibrillation. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(3):197-201. (In Russ.) https://doi.org/10.18705/1607-419X-2007-13-3-197-201